Treatment access study for pulmonary hypertension when no other option
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This Phase 3 study continues treatment for people with pulmonary hypertension who finished an earlier parent study and have no other approved treatment option. It tests whether continuing their current medicine can help them keep getting benefit and stay safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished the earlier parent study and can continue because it may still help you
- At the end of the parent study, you were taking macitentan by mouth, selexipag by mouth, or a macitentan+tadalafil fixed-dose pill
- You are willing to sign consent (or your legal representative will) and follow study procedures
- If you can get pregnant, pregnancy tests must be negative before starting and you must use contraception during the study and for 30 days after the last dose
- You must not be pregnant or breastfeeding, and you should not plan a pregnancy during the study
- Your blood counts, liver tests, and kidney function must be within allowed limits (or you must not have severe liver disease)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
This study provides continued access to an investigational inhaled medicine (treprostinil palmitil inhalation powder) for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD) who have already been in earlier studies of this treatment. It allows you to keep receiving the treatment under medical supervision.
This study tests an investigational drug (HS235) for people who have both heart failure with preserved ejection fraction and a type of pulmonary hypertension that can happen with it. The goal is to see if the drug can improve symptoms and quality of life.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This trial is for people with pulmonary arterial hypertension (PAH) who have already completed a previous study of the drug seralutinib. It offers continued access to the treatment so doctors can watch its safety and effects over a longer time.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
Hear when a new Hypertension, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.